Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes.
The purpose of this work was to compare the pharmacokinetics (PK) and tissue distribution of [14C]fluasterone following intravenous (iv), subcutaneous (sc) and oral (po) administration in male Beagle dogs. The main goal of the investigation was to discover if non-oral routes would alter parameters observed in this study following the administration of [14C]fluasterone. The oral formulation had a lower bioavailability (47%) compared to the sc formulation (84%). Po and sc administration resulted in a similar t(max); however, the observed C(max) following sc dosing was less than half of that after oral dosing. The sc route had the greatest overall exposure (AUC(0-infinity)). Tissue distribution analysis 2 h post-intravenous dosing showed that connective tissue (adipose and bone), liver, and skeletal muscle accumulated relatively high levels of fluasterone. The majority of the dose was retained during the first 24 h. Elimination of [14C]fluasterone-derived radioactivity following intravenous dosing resulted in urine and feces containing 7.6% and 28%, respectively, of the total dose over the first 24 h. Elimination of [14C]fluasterone-derived radioactivity following subcutaneous dosing resulted in 4.6% in urine and 7.8% in feces of the total dose over the first 24 h. Following oral dosing, elimination resulted in 3.8% in urine and 36% in feces over the first 24h. In conclusion, the sc route of administration offers some advantages to po and iv due to the prolonged release and increased retention through 24 h.
Lindeblad
Matthew O
MO
Toxicology Research Laboratory, Department of Pharmacology, University of Illinois at Chicago, 808 South Wood St., Rm. 1306, Chicago, IL 60612, USA.
Bauer
Kenneth S
KS
Zakharov
Alexander D
AD
Hill
Judith M
JM
Green
Jonathan S
JS
Thomas
Brian F
BF
Schwartz
Arthur
A
Kapetanovic
Izet M
IM
Lyubimov
Alexander
A
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D002250:Carbon Radioisotopes; D003687:Dehydroepiandrosterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004285:Dogs; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D014018:Tissue Distribution
D002250:Carbon Radioisotopes; D003687:Dehydroepiandrosterone; C106219:5-androstene-16-fluoro-17-one